All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lymphoma & CLL content recommended for you
Marco LadettoDuring the European School of Haematology (ESH)'s 2nd How to Diagnose & Treat Lymphoma conference, the Lymphoma Hub spoke to Marco Ladetto, SS Antonio e Biagio e Cesare Arrigo, Alessandria, IT, who discussed the role of autologous stem cell transplant (auto-SCT) for mantle cell lymphoma (MCL) in 2020.
Can we eliminate auto-SCT for patients with MCL?
Marco Ladetto starts by introducing what role auto-SCT plays in MCL and indicates that it must be considered in the context of full treatment protocols. He goes on to say, however, that medicine must continue to advance, and one way in which this can be done is through examination of the results of large phase III trials, such as TRIANGLE.
Ladetto discusses the heterogeneous nature of MCL and how different subsets respond to high-dose chemotherapy. The impact of some key mutations are also described.